• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Avantor Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    10/29/25 6:13:10 AM ET
    $AVTR
    Biotechnology: Laboratory Analytical Instruments
    Industrials
    Get the next $AVTR alert in real time by email
    avtr-20251029
    false000172248200017224822025-10-292025-10-29

    UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549
    FORM 8-K
    CURRENT REPORT
    Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
    Date of Report (Date of earliest event reported): October 29, 2025

    avantorlogoa08.jpg
    Avantor, Inc.
    (Exact name of registrant as specified in its charter)

    Delaware001-3891282-2758923
    (State or other jurisdiction of incorporation)(Commission File Number)(I.R.S. Employer Identification No.)
    Radnor Corporate Center, Building One, Suite 200
    100 Matsonford Road
    Radnor, Pennsylvania 19087
    (Address of principal executive offices, including zip code)
    (610) 386-1700
    (Registrant’s telephone number, including area code)
    Not Applicable
    (Former name or former address, if changed since last report)
    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
    ☐    Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
    ☐    Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
    ☐    Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
    ☐    Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))



    Securities registered pursuant to Section 12(b) of the Act:
    Title of each classTrading SymbolExchange on which registered
    Common Stock, $0.01 par valueAVTRNew York Stock Exchange
    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). ☐ Emerging growth company
    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐



    Item 2.02    Results of Operations and Financial Condition.
    On October 29, 2025, Avantor, Inc. issued a press release announcing its financial results for the quarter ended September 30, 2025. A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.
    The information contained in this Form 8-K (including Exhibit 99.1) shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, nor shall it be deemed incorporated by reference in any filing under the Securities Exchange Act of 1933, except as expressly set forth by specific reference in such a filing.
    Item 9.01    Financial Statements and Exhibits.
    (d) Exhibits
    Exhibit No.Description
    99.1
    Press release dated October 29, 2025
    104Cover Page Interactive File (the cover page tags are embedded within the Inline XBRL document)



    SIGNATURE
    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
    Avantor, Inc.
    Date: October 29, 2025By:/s/ Steven Eck
    Name:Steven Eck
    Title:Senior Vice President, Chief Accounting Officer (Principal Accounting Officer)


    Get the next $AVTR alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $AVTR

    DatePrice TargetRatingAnalyst
    10/30/2025$12.00Overweight → Equal Weight
    Barclays
    10/30/2025$12.00Overweight → Neutral
    Analyst
    8/1/2025Buy → Hold
    Jefferies
    4/29/2025$14.00Buy → Neutral
    Goldman
    4/28/2025$15.50Buy → Hold
    TD Cowen
    4/28/2025$14.00Buy → Hold
    Stifel
    4/28/2025Overweight → Equal-Weight
    Morgan Stanley
    1/17/2025$29.00 → $25.00Buy → Neutral
    UBS
    More analyst ratings

    $AVTR
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Avantor® Unveils Next-Generation Sterile Sampling Platform and PUPSIT Assemblies

    Integrated sterile sampling and PUPSIT solutions streamline bioprocessing, enhance flexibility, and reduce risk while accelerating in-process decisions RADNOR, Pa., Oct. 30, 2025 /PRNewswire/ -- Avantor, Inc. (NYSE:AVTR), a leading global provider of mission-critical products and services to customers in the life sciences and advanced technologies industries, today announced the launch of its pre-engineered PUPSIT (pre-use, post-sterilization integrity testing) assemblies and comprehensive sterile sampling suite. Designed to simplify qualification steps, reduce contamination risk, and support faster in-process decisions, the new suite of products gives manufacturers greater flexibility in ho

    10/30/25 8:05:00 AM ET
    $AVTR
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Avantor® Reports Third Quarter 2025 Results

    Net sales of $1.62 billion, decrease of 5%Net loss of $712 million and diluted GAAP loss per share of $1.04, including a non-cash goodwill impairment charge of $785 millionAdjusted EBITDA of $268 million; adjusted EPS of $0.22Operating cash flow of $207 million; free cash flow of $172 millionCompany announces $500 million share repurchase authorization, reflecting confidence in cash generation and commitment to driving long-term shareholder valueRADNOR, Pa., Oct. 29, 2025 /PRNewswire/ -- Avantor, Inc. (NYSE:AVTR), a leading global provider of mission-critical products and services to customers in the life sciences and advanced technology industries, today reported financial results for its t

    10/29/25 6:05:00 AM ET
    $AVTR
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Avantor® Announces Partnership with p-Chip Corporation to Develop Solutions for Digital Traceability of Smart Consumables

    New product line will enable secure chain-of-identity, enhanced traceability, and digital process control in pharmaceutical and clinical workflows – supporting the growing demand for individualized therapies RADNOR, Pa. and CHICAGO, Oct. 23, 2025 /PRNewswire/ -- Avantor, Inc. (NYSE:AVTR), a leading global provider of mission-critical products and services to customers in the life sciences and advanced technology industries, today announced a collaboration agreement with p-Chip Corporation to co-develop a new generation of "Smart Consumables" by embedding p-Chip's innovative microtransponder technology into Avantor's laboratory and clinical consumables.

    10/23/25 8:05:00 AM ET
    $AVTR
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $AVTR
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Summe Gregory L bought $1,125,000 worth of shares (100,000 units at $11.25) (SEC Form 4)

    4 - Avantor, Inc. (0001722482) (Issuer)

    10/31/25 9:46:22 AM ET
    $AVTR
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Director Lucier Gregory T was granted 8,736 shares (SEC Form 4)

    4 - Avantor, Inc. (0001722482) (Issuer)

    10/7/25 5:04:57 PM ET
    $AVTR
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    SEC Form 3 filed by new insider Lucier Gregory T

    3 - Avantor, Inc. (0001722482) (Issuer)

    10/7/25 5:02:06 PM ET
    $AVTR
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $AVTR
    SEC Filings

    View All

    SEC Form 10-Q filed by Avantor Inc.

    10-Q - Avantor, Inc. (0001722482) (Filer)

    10/29/25 9:01:46 AM ET
    $AVTR
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Avantor Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - Avantor, Inc. (0001722482) (Filer)

    10/29/25 6:13:10 AM ET
    $AVTR
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Avantor Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Termination of a Material Definitive Agreement, Creation of a Direct Financial Obligation, Other Events, Financial Statements and Exhibits

    8-K - Avantor, Inc. (0001722482) (Filer)

    10/14/25 4:46:20 PM ET
    $AVTR
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $AVTR
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    $AVTR
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Director Summe Gregory L bought $1,125,000 worth of shares (100,000 units at $11.25) (SEC Form 4)

    4 - Avantor, Inc. (0001722482) (Issuer)

    10/31/25 9:46:22 AM ET
    $AVTR
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Director Summe Gregory L bought $1,256,000 worth of shares (100,000 units at $12.56) (SEC Form 4)

    4 - Avantor, Inc. (0001722482) (Issuer)

    8/22/25 4:15:22 PM ET
    $AVTR
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Director Summe Gregory L bought $375,000 worth of shares (30,000 units at $12.50) (SEC Form 4)

    4 - Avantor, Inc. (0001722482) (Issuer)

    5/27/25 4:58:03 PM ET
    $AVTR
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Avantor downgraded by Barclays with a new price target

    Barclays downgraded Avantor from Overweight to Equal Weight and set a new price target of $12.00

    10/30/25 8:01:08 AM ET
    $AVTR
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Avantor downgraded by Analyst with a new price target

    Analyst downgraded Avantor from Overweight to Neutral and set a new price target of $12.00

    10/30/25 8:01:08 AM ET
    $AVTR
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Avantor downgraded by Jefferies

    Jefferies downgraded Avantor from Buy to Hold

    8/1/25 1:45:47 PM ET
    $AVTR
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $AVTR
    Leadership Updates

    Live Leadership Updates

    View All

    Avantor® Appoints Gregory T. Lucier to its Board of Directors

    Brings more than three decades of leadership experience in the life sciences industry RADNOR, Pa., Oct. 3, 2025 /PRNewswire/ -- Avantor, Inc. (NYSE:AVTR), a leading global provider of mission-critical products and services to customers in the life sciences and advanced technology industries, today announced the appointment of Gregory T. Lucier to its Board of Directors. Mr. Lucier brings significant experience and broad expertise across the healthcare landscape to the Avantor Board. He founded and serves as Executive Chairman and CEO of Corza Medical, a leading global manufact

    10/3/25 8:05:00 AM ET
    $AVTR
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Avantor® Appoints Dame Louise Makin, DBE, Ph.D., to its Board of Directors

    RADNOR, Pa., Nov. 6, 2024 /PRNewswire/ -- Avantor, Inc. (NYSE:AVTR), a leading global provider of mission-critical products and services to customers in the life sciences and advanced technology industries, announced that the Avantor Board of Directors has appointed Dame Louise Makin, DBE, Ph.D., as a director with an initial term expiring at Avantor's 2025 Annual Meeting of Stockholders. The appointment of Dame Louise as an independent director fills a vacant board seat. Dame Louise brings a wealth of leadership and industry experience to the Avantor Board. She served as Chief Executive Officer of BTG plc, an international specialist healthcare company, for 15 years and led their transform

    11/6/24 8:05:00 AM ET
    $AVTR
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Wheels Up Announces Gregory Summe to Join Board of Directors

    Veteran Leader Brings Deep Strategic, Aviation, and Governance Experience to Boardroom ATLANTA, Aug. 8, 2024 /PRNewswire/ -- Wheels Up Experience Inc. (NYSE:UP) today announced that Gregory L. Summe, Managing Partner of Glen Capital Partners LLC, joined its Board of Directors, effective August 7. Summe fills the unexpired term of David Adelman, who is stepping down to focus on other professional pursuits. Summe's initial term as a Class II director will continue until the 2026 annual meeting of the Company's stockholders. He will serve on the Audit and Compensation Committees

    8/8/24 8:05:00 AM ET
    $AVTR
    $GRAL
    $NXPI
    Biotechnology: Laboratory Analytical Instruments
    Industrials
    Medical Specialities
    Health Care

    $AVTR
    Financials

    Live finance-specific insights

    View All

    Avantor® Reports Third Quarter 2025 Results

    Net sales of $1.62 billion, decrease of 5%Net loss of $712 million and diluted GAAP loss per share of $1.04, including a non-cash goodwill impairment charge of $785 millionAdjusted EBITDA of $268 million; adjusted EPS of $0.22Operating cash flow of $207 million; free cash flow of $172 millionCompany announces $500 million share repurchase authorization, reflecting confidence in cash generation and commitment to driving long-term shareholder valueRADNOR, Pa., Oct. 29, 2025 /PRNewswire/ -- Avantor, Inc. (NYSE:AVTR), a leading global provider of mission-critical products and services to customers in the life sciences and advanced technology industries, today reported financial results for its t

    10/29/25 6:05:00 AM ET
    $AVTR
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Avantor® to Host Third Quarter 2025 Earnings Call on Wednesday, October 29, 2025

    RADNOR, Pa., Oct. 1, 2025 /PRNewswire/ -- Avantor, Inc. (NYSE:AVTR), a leading global provider of mission-critical products and services to customers in the life sciences and advanced technology industries, announced that it will release its third quarter 2025 financial results before the market opens on Wednesday, October 29, and will hold a conference call on the same day at 8:00 a.m. Eastern Time to discuss the results. To hear a live audio webcast of the session, visit Events & Presentations in the Investor section of Avantor's website, ir.avantorsciences.com. A replay of the webcast will be available for 30 days. About AvantorAvantor® is a leading life science tools company and global

    10/1/25 8:05:00 AM ET
    $AVTR
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Avantor® Reports Second Quarter 2025 Results

    Net sales of $1.68 billion, decrease of 1%; organic revenue was flatNet income of $65 million; Adjusted EBITDA of $280 millionDiluted GAAP EPS of $0.09; adjusted EPS of $0.24Operating cash flow of $154 million; free cash flow of $125 millionRADNOR, Pa., Aug. 1, 2025 /PRNewswire/ -- Avantor, Inc. (NYSE:AVTR), a leading global provider of mission-critical products and services to customers in the life sciences and advanced technology industries, today reported financial results for its second fiscal quarter ended June 30, 2025. "In the second quarter, we remained focused on driv

    8/1/25 6:05:00 AM ET
    $AVTR
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $AVTR
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Avantor Inc.

    SC 13G/A - Avantor, Inc. (0001722482) (Subject)

    11/14/24 1:28:33 PM ET
    $AVTR
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Amendment: SEC Form SC 13G/A filed by Avantor Inc.

    SC 13G/A - Avantor, Inc. (0001722482) (Subject)

    8/9/24 3:22:24 PM ET
    $AVTR
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Amendment: SEC Form SC 13G/A filed by Avantor Inc.

    SC 13G/A - Avantor, Inc. (0001722482) (Subject)

    8/7/24 4:09:12 PM ET
    $AVTR
    Biotechnology: Laboratory Analytical Instruments
    Industrials